CVRx, Inc. (CVRX) Dividend History

Company News

• CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

  CVRx's Barostim device has demonstrated significant reductions in hospital visits and length of stay for heart failure patients, according to new real-world evidence presented at the THT 2025 conference and published in the Journal of Cardiac Failure.

  GlobeNewswire Inc.
• CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

  CVRx, a medical device company, announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The company's Barostim System, which uses neuromodulation to improve heart failure symptoms, has received FDA approval and the CE Mark in the European Economic Area.

  GlobeNewswire Inc.
• Masimo Surges 8.7%: Is This an Indication of Further Gains?

  Masimo's shares surged 8.7% after the company's newly elected Board of Directors, proposed by activist investor Quentin Koffey, won election to the two available Board seats. Investors view this as a positive development, expecting the new Board to be more responsive to shareholders.

  Benzinga
• Bragar Eagel & Squire, P.C. Is Investigating Arhaus, Cardlytics, and CVRx and Encourages Investors to Contact the Firm

  Bragar Eagel & Squire, P.C. is investigating potential securities law violations by Arhaus, Cardlytics, and CVRx. The investigations focus on issues related to financial reporting, CEO departures, and reimbursement changes.

  GlobeNewswire Inc.

  Featured Companies: ARHS CDLX
• CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of CVRx, Inc. (CVRX) investors after the Centers for Medicare and Medicaid Services proposed payment rate cuts for CVRx's heart failure device, causing a significant drop in the company's stock price.

  GlobeNewswire Inc.